Cerebrolysin

Definition

Cerebrolysin is not a single peptide. It is a mixture of low-molecular-weight peptides and amino acids derived from pig brain ^[2], supplied as a solution for injection or infusion; the Austrian product information describes the active substance as a proteolytic peptide fraction from porcine brain protein and states that its short-chain peptides resemble or are identical to peptides present in the body, which is why its pharmacokinetics cannot be measured directly ^[1]. FDA's orphan-drug database files it under the descriptive name peptide fraction derived from porcine brain protein ^[19].

It is a licensed prescription medicine in Austria, where its marketing authorization dates from March 1996 and covers supportive treatment of cerebrovascular disorders, including Alzheimer-type and vascular dementia, deficits after stroke, and traumatic brain injury ^[1]. A Cochrane review describes it as widely used for acute ischemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries ^[2]. None of that confers any standing in the United States, where no application for it has ever been approved ^[13].

Evidence

Unlike most compounds in the neuropeptide class, Cerebrolysin has a substantial trial literature. Across its name variants PubMed returns 676 indexed records, of which 348 carry the Humans subject heading, 92 the clinical-trial publication type, and 63 the randomized-controlled-trial type ^[3]. The trials concentrate on three conditions: acute ischemic stroke, dementia, and traumatic brain injury.

In acute ischemic stroke the largest trial, CASTA, randomized 1,070 patients in Asia and found no significant difference between Cerebrolysin and placebo on its confirmatory endpoint; a post hoc analysis suggested a favorable trend in the most severely affected patients, which the investigators said should be confirmed by a further trial ^[4]. The CARS trial, which paired the drug with early rehabilitation, reported a large advantage on an arm-function score at day 90, and its authors described the study as exploratory, with a relatively small sample, and in need of confirmation ^[5]. The independent test of the stroke question is the Cochrane review, last updated in 2023: across 7 randomized trials with 1,773 participants, one of them of a similar peptide mixture, it found with moderate certainty that Cerebrolysin or that mixture probably makes little to no difference to death from any cause, and it noted that the manufacturer supported three of the multicenter studies ^[2]. A 2021 guideline from the European Academy of Neurology and the European Federation of Neurorehabilitation Societies nevertheless recommended Cerebrolysin, alongside citalopram, for early neurorehabilitation after acute ischemic stroke ^[6]; the review's primary measure was death from any cause, the guideline addressed early motor rehabilitation, and the two reached different conclusions.

The dementia evidence is weaker. A 2015 meta-analysis of 6 randomized trials in mild-to-moderate Alzheimer's disease reported benefit on global clinical change at 4 weeks and at 6 months, and on cognition at 4 weeks but not at 6 months ^[7]. A Cochrane review of Cerebrolysin in vascular dementia pooled 6 trials with 597 participants and graded its evidence very low quality; it concluded that any benefit may be too small to be clinically meaningful and that the supporting evidence base is weak ^[8].

In moderate-to-severe traumatic brain injury the CAPTAIN program ran two placebo-controlled trials. The first, with 46 patients, narrowly missed statistical significance on its primary endpoint in the intention-to-treat population ^[9]; the second, with 142 patients enrolled, reported a small-to-medium effect at day 90 ^[10]; a prospective meta-analysis of the two, covering 185 patients, reported the same size of effect ^[11]. Of the 42 studies that list Cerebrolysin as an intervention on ClinicalTrials.gov, the manufacturer is the most frequent lead sponsor, and none lists a site in the United States ^[12].

Side effects

The best-measured safety finding comes from the Cochrane review of acute ischemic stroke. Pooling three trials with 1,335 participants, it found that Cerebrolysin probably makes little to no difference to the total number of people with serious adverse events, but it also found, with moderate certainty, an increase in non-fatal serious adverse events, a risk ratio of 2.39 with a 95 percent confidence interval of 1.10 to 5.23 ^[2]. The review's conclusion names that as a potential increase; it is the one harm signal in the pooled trial evidence, and it comes from the independent review rather than from the manufacturer's trials.

The individual trials report a milder picture. CARS described the drug as safe and well tolerated ^[5], the CAPTAIN trials and their meta-analysis reported safety comparable to placebo ^{[9, 10, 11]}, and the 2015 Alzheimer's meta-analysis reported safety comparable to placebo ^[7]. The vascular dementia review found no difference in adverse effects but graded that evidence very low quality ^[8].

The Austrian product information lists the effects reported in use. Allergic or hypersensitivity reactions, ranging from skin and local vessel reactions, fever and chills to breathlessness and a shock-like state, are listed as very rare; agitation, including aggression, confusion and insomnia, loss of appetite, and dizziness with too-rapid administration are listed as rare; isolated grand mal seizures are listed as very rare ^[1]. The label contraindicates it in status epilepticus and severe kidney impairment, advises caution in people with allergic tendencies or epilepsy because seizure frequency may rise, and does not recommend it for anyone under 18 because the data are insufficient ^[1]. Material sold outside a licensed supply chain carries none of the quality controls that label assumes.

Educational summary of the cited sources, not medical advice; a prescriber weighs these risks against a person’s own history.

Lawful access

There is no approved Cerebrolysin product in the United States: Drugs@FDA holds no application for it under any name ^[13]. FDA did grant an orphan designation in April 2016 to the peptide fraction derived from porcine brain protein, sponsored by the Austrian manufacturer, for the treatment of frontotemporal dementia; the agency's database now lists that designation as withdrawn or revoked, and the product was never approved for the indication ^[19]. An orphan designation is an incentive for development and never an authorization to market.

Compounding offers no route either. A bulk substance with no USP or National Formulary monograph and no FDA-approved product behind it is eligible for 503A compounding only if it appears on the section 503A bulks list, or, pending that list, only if it was nominated with adequate support and has not been identified as a significant safety risk ^{[14, 15]}. FDA has twice stated in warning letters that Cerebrolysin had not been nominated for that list: in April 2020, to a Kentucky pharmacy whose investigators found it had compounded drug products from Cerebrolysin and twenty-one other substances ^[14], and again in November 2021, to an Indianapolis firm ^[15]. The substance appears in no category of the 503A list FDA published on May 14, 2026 ^[16], nowhere on FDA's Category 2 safety-risk page, including its table of nominations later withdrawn ^[17], and nowhere on the section 503B nominations list ^[18]. No list FDA has published since those letters names it, so it was no part of the April 2026 Category 2 removals or of the July 2026 advisory committee meeting.

The substance also appears in a criminal case. In October 2020 Tailor Made Compounding, a Kentucky pharmacy, pleaded guilty in federal court to distributing unapproved new drugs between October 2018 and April 2020; the Justice Department's account of the plea agreement names Cerebrolysin among them, and the company agreed to forfeit $1,788,906.82, its 2019 sales of those products ^[20]. Material sold under this name in the United States is outside approval, outside pharmacy compounding, and outside any trial; the research-only page sets out what that position means for a buyer.

Related molecules

Cerebrolysin is filed with the neuropeptides, where Semax is its nearest relative: both are stroke drugs registered abroad and never approved by FDA, and both are named in the same 2020 plea agreement. The difference is the dossier. The same 2020 and 2021 warning letters described both as not nominated; Semax was nominated afterward, passed through Category 2 and was recommended by the advisory committee in July 2026, while Cerebrolysin appears on no FDA list, so no committee has examined it. Dihexa, a dementia candidate with no human record, is the opposite case from a dementia drug with dozens of trials and the same absence of a US route.

The nominations tracker files every substance in this index by what became of its bulks-list nomination, and the human trial record prints Cerebrolysin's trial counts beside molecules with none, which is the clearest way to see that the size of a literature and the legal position are separate facts.

Elsewhere in this index